BERNS PAUL L

SEC source: 0001610717-26-000384 · form4.xml · derivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2036-08-20

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001012975-26-000565 · form4.xml · nonDerivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund XIII, L.P.

Disclosed balance after: 15,042,035

F1 · ownership.nature: These securities are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001193125-26-277936 · ownership.xml · derivative · entry 5

BERNS PAUL L · CIK 0001202769 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund XIII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 3,673,635 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: These securities are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001193125-26-277936 · ownership.xml · derivative · entry 4

BERNS PAUL L · CIK 0001202769 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund XIII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,917,731 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: These securities are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001193125-26-277936 · ownership.xml · derivative · entry 3

BERNS PAUL L · CIK 0001202769 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund XIII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 8,200,669 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: These securities are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001193125-26-277936 · ownership.xml · nonDerivative · entry 2

BERNS PAUL L · CIK 0001202769 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,706

F3 · kind: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

SEC source: 0001193125-26-277936 · ownership.xml · nonDerivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund XIII, L.P.

Disclosed balance after: 13,792,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: These securities are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001012975-26-000234 · form4.xml · nonDerivative · entry 1

ARCH Venture Fund XIII, L.P. · CIK 0002006772 · 10% owner

ARCH Venture Partners XIII, L.P. · CIK 0002016083 · 10% owner

ARCH Venture Partners XIII, LLC · CIK 0002016082 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

BERNS PAUL L · CIK 0001202769 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,426,528

F1 · ownership.nature: These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001610717-26-000052 · form4.xml · nonDerivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,395,185

F1 · kind: The shares were sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: This transaction was executed in multiple trades in prices ranging from $3.48 to $3.545, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001610717-26-000008 · form4.xml · derivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,650,000

Underlying: Common Stock · 1,650,000 shares

Expires 2036-01-08

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001193125-25-280813 · ownership.xml · derivative · entry 7

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 223,430 shares

Expires 2034-11-11

F3 · security: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,

F4 · security: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.

F3 · price: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,

F4 · price: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.

F7 · derivative.exercise_date: This option provided for vesting in 36 substantially equal monthly installments from November 12, 2024.

SEC source: 0001193125-25-280813 · ownership.xml · derivative · entry 6

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,188 shares

Expires 2035-05-19

F3 · security: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,

F4 · security: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.

F3 · price: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,

F4 · price: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.

F6 · derivative.exercise_date: This option provided for vesting in 12 substantially equal monthly installments from May 20, 2025.

SEC source: 0001193125-25-280813 · ownership.xml · derivative · entry 5

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,031

Underlying: Common Stock · 4,031 shares

Expires not disclosed

F5 · price: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. There is no vesting applicable to the cash payment and the CVRs.

F5 · derivative.exercise_date: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. There is no vesting applicable to the cash payment and the CVRs.

F5 · derivative.expiration_date: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. There is no vesting applicable to the cash payment and the CVRs.

SEC source: 0001193125-25-280813 · ownership.xml · nonDerivative · entry 4

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus

F2 · kind: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

F1 · price: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus

F2 · price: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

SEC source: 0001193125-25-280813 · ownership.xml · nonDerivative · entry 3

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus

F2 · kind: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

F1 · price: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus

F2 · price: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

F8 · ownership.nature: Represents shares of Common Stock held directly by ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.

SEC source: 0001193125-25-280813 · ownership.xml · nonDerivative · entry 2

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus

F2 · kind: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

F1 · price: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus

F2 · price: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

F8 · ownership.nature: Represents shares of Common Stock held directly by ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.

SEC source: 0001193125-25-280813 · ownership.xml · nonDerivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus

F2 · kind: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

F1 · price: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus

F2 · price: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

F5 · price: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. There is no vesting applicable to the cash payment and the CVRs.

SEC source: 0000950170-25-079920 · ownership.xml · derivative · entry 8

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Common Stock · 2,000,000 shares

Expires 2035-02-13

F6 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-079920 · ownership.xml · derivative · entry 7

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 342,500

Underlying: Common Stock · 342,500 shares

Expires 2034-02-14

F6 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-079920 · ownership.xml · derivative · entry 6

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 955,864

Underlying: Common Stock · 955,864 shares

Expires 2033-06-28

F6 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from July 3, 2023 (the "Vesting Commencement Date.), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-079920 · ownership.xml · derivative · entry 5

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 497,049

Underlying: Common Stock · 497,049 shares

Expires 2032-01-27

F6 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-079920 · ownership.xml · derivative · entry 4

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,000,000 shares

Expires 2035-02-13

F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-079920 · ownership.xml · derivative · entry 3

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 342,500 shares

Expires 2034-02-14

F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-079920 · ownership.xml · derivative · entry 2

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 955,864 shares

Expires 2033-06-28

F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from July 3, 2023 (the "Vesting Commencement Date.), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-079920 · ownership.xml · derivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 497,049 shares

Expires 2032-01-27

F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-076566 · ownership.xml · derivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,188

Underlying: Common Stock · 24,188 shares

Expires 2035-05-19

F1 · derivative.exercise_date: The options will vest and become exercisable in 12 substantially equal monthly installments after the date of grant, such that the option will be vested in full on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0001610717-25-000031 · form4.xml · nonDerivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,405,004

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 19, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.

F2 · price: This transaction was executed in multiple trades in prices ranging from $1.66 to $1.745, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0000950170-25-022323 · ownership.xml · derivative · entry 7

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 342,500

Underlying: Common Stock · 342,500 shares

Expires 2034-02-14

F6 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-022323 · ownership.xml · derivative · entry 6

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 955,864

Underlying: Common Stock · 955,864 shares

Expires 2033-06-28

F6 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from July 3, 2023 (the "Vesting Commencement Date.), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-022323 · ownership.xml · derivative · entry 5

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 497,049

Underlying: Common Stock · 497,049 shares

Expires 2032-01-27

F6 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-022323 · ownership.xml · derivative · entry 4

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 342,500 shares

Expires 2034-02-14

F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-022323 · ownership.xml · derivative · entry 3

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 955,864 shares

Expires 2033-06-28

F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from July 3, 2023 (the "Vesting Commencement Date.), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-022323 · ownership.xml · derivative · entry 2

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 497,049 shares

Expires 2032-01-27

F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-022323 · ownership.xml · derivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Common Stock · 2,000,000 shares

Expires 2035-02-13

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000950170-25-012583 · ownership.xml · derivative · entry 5

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,139,951 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723. The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering.

F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723. The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723. The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723. The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.

SEC source: 0000950170-25-012583 · ownership.xml · derivative · entry 4

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 6,383,731 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723. The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering.

F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723. The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723. The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723. The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.

SEC source: 0000950170-25-012583 · ownership.xml · nonDerivative · entry 2

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,313,680

F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.

SEC source: 0000950170-25-012583 · ownership.xml · nonDerivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 7,523,682

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723. The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.

SEC source: 0001610717-24-000555 · form4.xml · nonDerivative · entry 5

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,418,875

F1 · kind: On December 27, 2024, the Reporting Person transferred, for no consideration, 133,097 shares of Common Stock to each of LULU TRUST OF 2024 FBO AB, LULU TRUST OF 2024 FBO OB, and LULU TRUST OF 2024 FBO HB, of which members of the Reporting Person's immediate family are the sole beneficiaries.

SEC source: 0001610717-24-000555 · form4.xml · nonDerivative · entry 3

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,551,972

F1 · kind: On December 27, 2024, the Reporting Person transferred, for no consideration, 133,097 shares of Common Stock to each of LULU TRUST OF 2024 FBO AB, LULU TRUST OF 2024 FBO OB, and LULU TRUST OF 2024 FBO HB, of which members of the Reporting Person's immediate family are the sole beneficiaries.

SEC source: 0001610717-24-000555 · form4.xml · nonDerivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,685,069

F1 · kind: On December 27, 2024, the Reporting Person transferred, for no consideration, 133,097 shares of Common Stock to each of LULU TRUST OF 2024 FBO AB, LULU TRUST OF 2024 FBO OB, and LULU TRUST OF 2024 FBO HB, of which members of the Reporting Person's immediate family are the sole beneficiaries.

SEC source: 0000950170-24-076288 · ownership.xml · derivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 21, 2024 or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.

SEC source: 0001610717-24-000066 · form4.xml · derivative · entry 2

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 342,500

Underlying: Common Stock · 342,500 shares

Expires 2034-02-13

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000066 · form4.xml · nonDerivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,818,166

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0000899243-23-020307 · doc4.xml · derivative · entry 3

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 86,344 shares

Expires 2024-12-17

F5 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 86,344 shares of Issuer common stock (the "Earn-out Shares"), (i) 60,441 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 25,903 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50.

F6 · derivative.exercise_price: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement.

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines.

F5 · price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 86,344 shares of Issuer common stock (the "Earn-out Shares"), (i) 60,441 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 25,903 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50.

F6 · price: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement.

F2 · derivative.exercise_date: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F7 · derivative.exercise_date: Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement.

SEC source: 0000899243-23-020307 · doc4.xml · derivative · entry 2

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 101,010 shares

Expires 2032-09-30

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time.

F4 · derivative.exercise_date: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).

SEC source: 0000899243-23-020307 · doc4.xml · nonDerivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines.

F2 · price: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

SEC source: 0000899243-23-016505 · doc4.xml · derivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2033-06-22

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 23, 2023 or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.

SEC source: 0001104659-23-001121 · tm231679-8_4seq1.xml · derivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,344

Underlying: Common Stock · 453 shares

Expires 2024-12-17

F1 · derivative.exercise_price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 453 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 317 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 136 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).

F1 · kind: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 453 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 317 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 136 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).

F1 · price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 453 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 317 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 136 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).

F1 · derivative.exercise_date: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 453 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 317 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 136 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).

SEC source: 0001104659-22-106015 · tm2227449-3_4seq1.xml · derivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,010

Underlying: Common Stock · 101,010 shares

Expires 2032-09-30

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full September 30, 2023, the one-year anniversary of the grant date, subject to the Reporting Person's continuous service on such vesting date, and subject to full acceleration upon the consummation of a Sale Event (as defined in the Issuer's 2021 Stock Option and Incentive Plan).